-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Erasca (NASDAQ:ERAS) Trading 3.4% Higher
Erasca (NASDAQ:ERAS) Trading 3.4% Higher
Shares of Erasca, Inc. (NASDAQ:ERAS – Get Rating) traded up 3.4% on Friday . The company traded as high as $4.33 and last traded at $4.26. 19,904 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,558,398 shares. The stock had previously closed at $4.12.
Erasca Price Performance
The firm has a market cap of $527.37 million, a PE ratio of -3.72 and a beta of 0.99. The business has a 50-day moving average price of $6.47 and a two-hundred day moving average price of $7.22.
Get Erasca alerts:Erasca (NASDAQ:ERAS – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.02. Equities analysts expect that Erasca, Inc. will post -1.2 earnings per share for the current fiscal year.
Insider Activity at Erasca
In related news, Director Bihua Chen acquired 307,692 shares of the firm's stock in a transaction that occurred on Tuesday, December 13th. The shares were acquired at an average price of $6.50 per share, with a total value of $1,999,998.00. Following the completion of the purchase, the director now directly owns 10,813,246 shares in the company, valued at $70,286,099. The purchase was disclosed in a document filed with the SEC, which is available through this link. In other Erasca news, Director Valerie Denise Harding Start purchased 10,000 shares of the firm's stock in a transaction on Wednesday, December 21st. The shares were purchased at an average cost of $4.64 per share, with a total value of $46,400.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $46,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bihua Chen purchased 307,692 shares of the firm's stock in a transaction on Tuesday, December 13th. The stock was acquired at an average cost of $6.50 per share, for a total transaction of $1,999,998.00. Following the completion of the purchase, the director now owns 10,813,246 shares in the company, valued at approximately $70,286,099. The disclosure for this purchase can be found here. Insiders have purchased a total of 377,692 shares of company stock valued at $2,343,398 over the last quarter. Insiders own 37.50% of the company's stock.Institutional Trading of Erasca
A number of hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Erasca in the 2nd quarter valued at about $27,000. Ameritas Investment Partners Inc. lifted its stake in shares of Erasca by 212.7% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,957 shares of the company's stock valued at $43,000 after purchasing an additional 3,372 shares in the last quarter. Amalgamated Bank acquired a new position in shares of Erasca in the 1st quarter valued at about $64,000. Teacher Retirement System of Texas acquired a new position in shares of Erasca in the 3rd quarter valued at about $78,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of Erasca in the 3rd quarter valued at about $79,000. 65.75% of the stock is owned by institutional investors and hedge funds.
About Erasca
(Get Rating)
Erasca, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors.
Featured Articles
- Get a free copy of the StockNews.com research report on Erasca (ERAS)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.
埃拉斯卡股份有限公司(纳斯达克代码:ERAS-GET Rating)股价周五上涨3.4%。该公司股价一度高达4.33美元,最新报4.26美元。午盘成交量为19,904股,较1,558,398股的平均成交量下降99%。该股此前收盘价为4.12美元。
伊拉斯卡的性价比
该公司市值为5.2737亿美元,市盈率为-3.72,贝塔系数为0.99。该业务的50日移动均线价格为6.47美元,200日移动均线价格为7.22美元。
到达埃拉斯卡警报:埃拉斯卡(纳斯达克代码:ERAS-GET Rating)上一次公布季度收益数据是在11月9日星期三。该公司公布了该季度每股收益(0.29美元),比分析师普遍预期的(0.31美元)高出0.02美元。股票分析师预计,Erasca,Inc.将公布本财年每股收益为1.2美元。
埃拉斯卡的内幕活动
在相关新闻中,董事陈碧华在12月13日(星期二)的一笔交易中收购了307,692股该公司的股票。这些股票是以每股6.50美元的平均价格收购的,总价值为1,999,998.00美元。收购完成后,董事现在直接拥有该公司10,813,246股,价值70,286,099美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过这个环节。其他方面,董事瓦莱丽·丹尼斯·哈丁·斯塔特在12月21日星期三的一次交易中购买了10,000股该公司股票。这些股票是以每股4.64美元的平均成本购买的,总价值为46,400.00美元。收购完成后,董事现在拥有该公司1万股,价值4.64万美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过这个环节。此外,陈碧华在12月13日(星期二)的一笔交易中购买了307,692股董事股票。收购股票的平均成本为每股6.50美元,交易总额为1,999,998.00美元。收购完成后,董事现在拥有该公司10,813,246股,价值约70,286,099美元。关于这次购买的披露可以找到这里。在上个季度,内部人士总共购买了377,692股公司股票,价值2,343,398美元。内部人士持有该公司37.50%的股份。伊拉斯卡的机构交易
一些对冲基金最近增持或减持了该业务的股份。Zurcher Kantonalbank苏黎世广东银行在第二季度收购了价值约2.7万美元的Erasca股票的新头寸。Ameritas Investment Partners Inc.在第一季度增持了212.7%的Erasca股票。Ameritas Investment Partners Inc.目前持有4,957股该公司股票,价值43,000美元,该公司在上个季度又购买了3,372股。合并银行在第一季度收购了Erasca股票的新头寸,价值约6.4万美元。德克萨斯州教师退休系统在第三季度收购了Erasca股票的新头寸,价值约7.8万美元。最后,Price T Rowe Associates Inc.MD在第三季度收购了价值约7.9万美元的Erasca股票的新头寸。65.75%的股票由机构投资者和对冲基金持有。
关于伊拉斯卡
(获取评级)
Erasca公司是一家临床阶段的生物制药公司,专注于发现、开发和商业化RAS/MAPK途径驱动的癌症患者的治疗方法。该公司的主要候选药物包括ERK1/2口服抑制剂ERK1/2,用于治疗非小细胞肺癌、结直肠癌和急性髓系白血病;以及ERAS-601,一种用于晚期或转移性实体肿瘤患者的口服SHP2抑制剂。
专题文章
- 免费获取StockNews.com关于Erasca的研究报告(Era)
- MarketBeat:回顾一周12/26-12/30
- 科技狗:是时候咬一口这些股票了
- 这笔收购会让微软成为熊市买入者吗?
- 金塔拉治疗公司是一颗隐藏的宝石吗?
- 你应该热身到Generac股票过冬吗?
接受《Erasca Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Erasca和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧